First-line nivolumab (NIVO) plus ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA

Reck, M.Ciuleanu, T-E.Cobo, M.Schenker, M.Zurawski, B.Menezes, J.Richardet, E.Bennouna, J.Cheng, Y.Paz-Ares, L.Lu, S.John, T.Padilla, B.Sun, X.Moisei, A.Yan, J.Yuan, Y.Blum, S. I.Carbone, D. P.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/24352enFirst-line nivolumab (NIVO) plus ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LAconference outputopen access10.1016/j.annonc.2020.08.22921569-8041http://www.annalsofoncology.org/article/S0923753420423749/pdf573469102690